The Vetr crowd on Wednesday upgraded its rating on Bristol-Myers Squibb Company BMY from 3 stars (Hold), issued 12 days ago, to 3.5 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.
Shares price in the biotech comapny has remained in range for the better part of Q4, finding recent support around the $61 area. The stock reached that floor again Wednesday for the third time in the past month and finished the day at $61.20
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average price target on Bristol-Myers is up at $64.91, which is higher than the average analyst price target of $62.35. Less than 2 percent of Vetr users are holding BMY in their watch-lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
